Thursday, April 9, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 9, 2026
Biogen settles investor lawsuit over its messaging on failed Alzheimer's drug Aduhelm
background ▾
- •Biogen resolves investor litigation over Aduhelm approval messaging, reducing ongoing legal exposure from the failed Alzheimer's program
- •Settlement reflects significant reputational and financial consequences of the controversial 2021 accelerated approval, which faced widespread scrutiny from clinicians, payers, and regulators
- •Case establishes precedent for investor claims based on drug approval communications; companies face heightened disclosure obligations when seeking or obtaining accelerated pathways with limited data
BiogenAduhelm (aducanumab)
→ Read original articlePolicy•Pharmaceutical Technology•Apr 9, 2026
FDA seeks permanent future for rare pediatric priority review vouchers
background ▾
- •FDA seeks permanent reauthorization of the rare pediatric disease PRV program to eliminate cyclical congressional renewals and create stable regulatory conditions for pediatric drug development
- •Since inception in 2014, the program has awarded 63 vouchers across 47 rare pediatric diseases, with 43 of those diseases gaining their first-ever FDA-approved treatment
- •The secondary market for PRVs has matured significantly, with Jazz Pharmaceuticals selling a voucher for $200 million in January 2026, indicating substantial commercial value dependent on program stability
Jazz Pharmaceuticals
→ Read original articlePolicy•Pharmaceutical Technology•Apr 8, 2026
Pharma industry laments Trump’s tariff on branded drugs
background ▾
- •The 100% tariff applies narrowly to branded drugs from countries without trade deals (Singapore, India, China) that currently export minimal branded pharmaceuticals to the US, limiting immediate economic impact but signaling intensified US-China biotech competition
- •Major pharma companies are substantially protected via existing MFN agreements (16 firms through 2029) and incentives for domestic manufacturing, fragmenting the tariff's intended effect and creating competitive advantage for already-large players
- •Watch for: enforcement timeline beginning in 4-6 months, extent of industry pivot toward onshore production, potential retaliation from trading partners, and whether China counters with restrictions on biotech licensing or APIs to US companies
PfizerEli LillyMSD
→ Read original articlePolicy•STAT News•Apr 9, 2026
Opinion: As a palliative care physician, I’m nervous about the Medicare infusion of $100 million for ‘functional or lifestyle medicine’
background ▾
- •MAHA ELEVATE's $100 million investment in functional/lifestyle medicine could inadvertently legitimize and fund interventions lacking rigorous evidence, particularly risky in palliative care where symptom subjectivity and prognostic uncertainty create conditions favoring confident-but-untestable narratives
- •Evidence shows 88% of terminally ill palliative care patients use complementary/alternative medicine, and complementary medicine use in cancer patients is associated with twice the risk of death due to conventional treatment refusal—underscoring the real clinical stakes
- •Watch how CMS implements accountability mechanisms in MAHA ELEVATE funding, whether funded interventions maintain evidence standards as a prerequisite for Medicare coverage, and whether the program establishes guardrails preventing displacement of proven conventional treatments
Policy•Fierce Biotech•Apr 8, 2026
Medline hit with FDA warning letter over defective heart syringes, safety hazards
background ▾
- •FDA identified air embolism risk (potentially fatal) from loose syringe-manifold connections due to excess silicone, with documented patient injury and clinician exposure incidents across 221 complaints
- •Medline's internal risk assessment classified the defect as 'low risk' despite company's own Health Hazard Evaluation identifying air embolism as highest-severity issue—a material gap that triggered FDA enforcement action
- •Watch for outcome of Medline's recall execution, any follow-up FDA inspections, potential litigation from affected healthcare systems/patients, and impact on investor confidence post-IPO
Medline IndustriesNAMIC Angiographic Control Syringes
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 8, 2026
Fierce Biotech Fundraising Tracker '26: Life Bio lures $80M; Sidewinder snares $150M
background ▾
- •Eight biotech companies raised over $900M across tracked rounds, with oncology-focused programs (ADCs, bispecific antibodies) and metabolic/GLP-1 therapies dominating the capital allocation landscape
Life BiosciencesSidewinder TherapeuticsStipple BioER-100STP-100bretisilocin
→ Read original articleMarket Access•Fierce Biotech•Apr 8, 2026
Artivion nabs PMA clearance for aortic stent graft system, triggers Endospan buyout option
background ▾
- •FDA PMA clearance for Nexus Triomphe aortic stent graft system opens a significant new market for minimally invasive aortic arch disease treatment with strong 1-year safety and efficacy data (90% survival, 90% stroke-free, 98% endoleak-free)
- •Acquisition option triggered: Artivion can acquire Endospan for $150 million within 90 days, with financing already in place, consolidating a key technology platform
- •Watch for shareholder update on acquisition decision and commercial launch timeline; this builds on Artivion's recent aortic disease franchise expansion (AMDS approval in 2023)
ArtivionEndospanNexus TriompheAMDS Hybrid Prosthesis
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 9, 2026
EverSea Medicines to acquire Hasten Biopharmaceuticals
background ▾
- •Everest Medicines acquires 14 established branded products with $82.23M annual revenue and $27.27M EBITDA, immediately adding commercial revenue and regional market presence
- •Deal structure ($150M upfront + $100M earnouts through 2029) ties future payments to performance, indicating confidence but also execution risk
- •Acquisition accelerates Everest's strategy to transition from pipeline-dependent biotech to integrated commercial player across Asia Pacific, supporting faster market entry for Nefecon, Velsipity, and Xerava
Everest MedicinesEverSea MedicinesHasten BiopharmaceuticalsNefeconVelsipityXerava
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 7, 2026
Gilead outlays $5bn to acquire ADC specialist Tubulis
background ▾
- •Gilead's aggressive 2026 M&A strategy ($5bn Tubulis + $7.8bn Arcellx + $2.2bn Ouro Medicines) signals major oncology expansion following strong Trodelvy commercial performance ($1.4bn sales in 2025)
- •TUB-040 showed positive safety and efficacy in platinum-resistant ovarian cancer Phase Ib/II data (October 2025), representing a meaningful clinical-stage asset in a high-unmet-need indication
- •ADC market projected to reach $65.2bn by 2031 with 11 products at blockbuster status; watch TUB-040 Phase II progression, Arcellx cell therapy launch timing, and Trodelvy's ability to maintain growth momentum against incoming ADC competition
Gilead SciencesTubulisBristol Myers SquibbTUB-040TUB-030Trodelvy (sacituzumab govitecan-hziy)
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 8, 2026
Halozyme and Vertex sign deal for Hypercon technology
background ▾
- •Vertex licenses Halozyme's Hypercon technology exclusively for up to three targets with $15M upfront plus milestones and royalties, signaling commercial validation of microparticle hyperconcentration for at-home biologics delivery
- •This follows Halozyme's January 2026 Takeda collaboration on vedolizumab with Enhanze, indicating growing pharma adoption of Halozyme's drug delivery platform across multiple licensees
- •Watch for: Vertex pipeline applications using Hypercon, clinical trial initiation timelines, and competitive responses from other drug delivery platform vendors
Halozyme TherapeuticsVertex PharmaceuticalsTakedaEnhanzevedolizumab
→ Read original articleClinical Trials
Clinical Trials•Pharmaceutical Technology•Apr 8, 2026
Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
background ▾
- •Sidewinder's bispecific ADC platform targets dual receptor co-complexes to achieve enhanced selectivity and reduced off-target toxicity—a differentiation strategy from first-generation ADCs in a rapidly crowded field
- •Three clinical-stage assets planned within 18 months (SWT012 IND end-2026; SWT019/SWT020 IND/DC nomination H1 2027) positions Sidewinder to advance preclinical bladder, lung, and colorectal cancer candidates
- •Monitor IND approvals and clinical readout timelines (2026–2027) as validation points; broader market watch includes Phase III bispecific ADC programs (e.g., BMS/Systimmune izalontamab brengitecan) that will shape competitive landscape and reimbursement expectations
Sidewinder TherapeuticsNovartisFrazier Life SciencesSWT012SWT019SWT020
→ Read original articleClinical Trials•STAT News•Apr 8, 2026
Smart contact lens monitors eye pressure and delivers glaucoma drugs in early tests
background ▾
- •Novel passive mechanism (corneal shape changes trigger drug release from microfluidic chamber) eliminates need for battery, electronics, or rigid components—addressing the comfort and practicality limitations of existing wearable IOP sensors like Sensimed's Triggerfish
- •Early-stage preclinical validation in animal models; significant development milestones remain before human trials and FDA approval
- •Watch for advancement to human clinical trials, manufacturing scale-up feasibility, drug stability/shelf life data, and regulatory guidance on combination device-drug classification
Terasaki Institute for Biomedical InnovationSensimedVerily
→ Read original articleClinical Trials•Fierce Pharma•Apr 9, 2026
Insmed terminates development of Brinsupri in another indication after midstage HS flop
background ▾
- •Brinsupri has now failed two separate midstage expansion trials within four months, indicating potential fundamental limitations in the drug's therapeutic scope
- •Insmed is de-risking its pipeline by terminating development, suggesting management has lost confidence in the asset's ability to generate meaningful value beyond its current indication
- •Investors and analysts should monitor whether Insmed diverts resources to other pipeline assets or whether additional Brinsupri indications remain in development
InsmedBrinsupri
→ Read original articleClinical Trials•STAT News•Apr 8, 2026
Team approach to lowering high blood pressure worked even in ‘a tough landscape’
background ▾
- •Team-based, protocol-driven hypertension management achieved significant BP reductions in low-income patients—the first RCT demonstrating this approach works in federally qualified health centers
- •The intervention incorporated home BP monitoring with frequent feedback, systematic medication titration, and community health worker coaching based on SPRINT trial principles
- •Study conducted successfully across 18 months including COVID-19 disruptions in two of the poorest U.S. states, strengthening external validity for resource-limited settings
Clinical Trials•Fierce Biotech•Apr 8, 2026
Akari locks arms with WuXi XDC to develop and manufacture novel ADC treatment
background ▾
- •AKTX-101, featuring a first-in-kind RNA splicing-modulating ADC payload, is progressing toward phase 1 initiation in late 2026/early 2027 with secured manufacturing partnership
- •WuXi XDC partnership provides end-to-end development and manufacturing support, reducing Akari's operational risk in bringing a novel payload class into human studies
Akari TherapeuticsWuXi XDCAKTX-101
→ Read original article